Surface-engineered hyaluronic acid-coated lyotropic liquid crystalline nanoparticles for CD44-targeting of 3-Acetyl-11-keto-β-boswellic acid in rheumatoid arthritis treatment.

ABSTRACT:

Background

In the current era of the global increase in autoimmune and inflammatory disorders, predominantly rheumatoid arthritis (RA), there is mounting interest in developing advanced, safe, and patient-compliant treatment strategies. Phytoconstituents have gained more attention in recent years as budding complementary medicines for RA. Among them, 3-Acetyl-11-keto-β-boswellic acid (AKBA), derived from Boswellia serrata extract, is considered a promising phytoconstituent due to its anti-inflammatory and anti-arthritic potential. However, due to its poor solubility, low bioavailability (less than 10%), and poor permeability, its therapeutic potential is limited. Therefore, to overcome these issues, we have developed novel hyaluronic acid-surface-engineered lyotropic liquid crystal

SUBMITTER: Priya S 

PROVIDER: S-EPMC12632076 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature